Clinicopathological Correlates of Ocular Surface Squamous Neoplasia

Overview

Journal Ocul Oncol Pathol

Date 2024 Jun 17

PMID 38882020

Authors

Timothy Kalas

Dimitrios Vagenas

Luke Maccheron

Nicholas Toalster

Affiliations

Soon will be listed here.

Abstract

Introduction: This study examined the distribution of histopathological disease severity amongst a cohort of patients treated for clinically suspected ocular surface squamous neoplasia and evaluated the relationship between various patient and clinical factors and the severity of pathological grade as well as treatment outcomes.

Methods: A retrospective cohort study of demographic and clinicopathological factors of 150 patients clinically diagnosed with suspected ocular surface squamous neoplasia who underwent excision of lesion with histopathological diagnosis.

Results: The study included 125 cases; the mean age at diagnosis was 64 years (SD = 11.26). 74% of cases were histologically confirmed as ocular surface squamous neoplasia. Pathological distribution was conjunctival intraepithelial neoplasia I (13.6%), conjunctival intraepithelial neoplasia II (16.8%), conjunctival intraepithelial neoplasia III (21.6%), carcinoma in situ (21.6%), and squamous cell carcinoma (2.4%). Lesion appearance was leukoplakic (18%), gelatinous (15%), dysplastic (11%), vascular (6%), papilliform (2%), nodular (2%). Lesion location was nasal (43%), temporal (42%), and superior or inferior (14%). Recurrence occurred in 7 cases (5.6%). A significant association was found between presence of leukoplakia and pathological grade ( = 0.05).

Conclusions: Ocular surface squamous neoplasia is most frequently diagnosed in conjunctival intraepithelial neoplasia III and carcinoma in situ stages, and treatment outcomes are usually favourable.

References

Dandala P, Malladi P, Kavitha . Ocular Surface Squamous Neoplasia (OSSN): A Retrospective Study. J Clin Diagn Res. 2015; 9(11):NC10-3. PMC: 4668444. DOI: 10.7860/JCDR/2015/16207.6791. View

Venkateswaran N, Mercado C, Galor A, Karp C . Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia. Am J Ophthalmol. 2018; 199:216-222. PMC: 6382615. DOI: 10.1016/j.ajo.2018.11.007. View

Theotoka D, Morkin M, Galor A, Karp C . Update on Diagnosis and Management of Conjunctival Papilloma. Eye Vis (Lond). 2019; 6:18. PMC: 6580461. DOI: 10.1186/s40662-019-0142-5. View

Lee G, Hirst L . Retrospective study of ocular surface squamous neoplasia. Aust N Z J Ophthalmol. 1997; 25(4):269-76. DOI: 10.1111/j.1442-9071.1997.tb01514.x. View

Tananuvat N, Niparugs M, Wiwatwongwana D, Lertprasertsuk N, Mahanupap P . Ocular surface squamous neoplasia in Northern Thailand: a 16-year review. BMC Ophthalmol. 2022; 22(1):121. PMC: 8918314. DOI: 10.1186/s12886-022-02340-y. View

Tabin G, Levin S, Snibson G, Loughnan M, Taylor H . Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology. 1997; 104(3):485-92. DOI: 10.1016/s0161-6420(97)30287-5. View

Mishra D, Taneja S, Singh V, Veena U, Kaliki S . Histopathological spectrum of ocular surface squamous neoplasia: A retrospective study of 776 lesions. Indian J Pathol Microbiol. 2022; 65(1):3-7. DOI: 10.4103/IJPM.IJPM_1313_20. View

Waddell K, Downing R, Lucas S, Newton R . Corneo-conjunctival carcinoma in Uganda. Eye (Lond). 2006; 20(8):893-9. DOI: 10.1038/sj.eye.6702043. View

Lee G, Hirst L . Ocular surface squamous neoplasia. Surv Ophthalmol. 1995; 39(6):429-50. DOI: 10.1016/s0039-6257(05)80054-2. View

10.

Makupa I, Swai B, Makupa W, White V, Lewallen S . Clinical factors associated with malignancy and HIV status in patients with ocular surface squamous neoplasia at Kilimanjaro Christian Medical Centre, Tanzania. Br J Ophthalmol. 2011; 96(4):482-4. DOI: 10.1136/bjophthalmol-2011-300485. View

11.

Alley S, Duncan M, Schoeppe S, Rebar A, Vandelanotte C . 8-year trends in physical activity, nutrition, TV viewing time, smoking, alcohol and BMI: A comparison of younger and older Queensland adults. PLoS One. 2017; 12(3):e0172510. PMC: 5332140. DOI: 10.1371/journal.pone.0172510. View

12.

Lee G, Williams G, Hirst L, Green A . Risk factors in the development of ocular surface epithelial dysplasia. Ophthalmology. 1994; 101(2):360-4. DOI: 10.1016/s0161-6420(94)31328-5. View

13.

Kaliki S, Vempuluru V, Ghose N, Gunda S, Vithalani N, Sultana S . Ocular surface squamous neoplasia in India: a study of 438 patients. Int Ophthalmol. 2022; 42(6):1915-1926. DOI: 10.1007/s10792-021-02189-y. View

14.

Tiong T, Borooah S, Msosa J, Dean W, Smith C, Kambewa E . Clinicopathological review of ocular surface squamous neoplasia in Malawi. Br J Ophthalmol. 2013; 97(8):961-4. DOI: 10.1136/bjophthalmol-2012-302533. View

15.

Newton R, Ferlay J, Reeves G, Beral V, Parkin D . Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. Lancet. 1996; 347(9013):1450-1. DOI: 10.1016/s0140-6736(96)91685-2. View

16.

Hllhumer R, Williams S, Michelow P . Ocular surface squamous neoplasia: management and outcomes. Eye (Lond). 2021; 35(6):1562-1573. PMC: 8169825. DOI: 10.1038/s41433-021-01422-3. View

17.

Galor A, Karp C, Oellers P, Kao A, Abdelaziz A, Feuer W . Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology. 2012; 119(10):1974-81. PMC: 3459154. DOI: 10.1016/j.ophtha.2012.04.022. View

18.

Hussain I, Khan B . Ocular Surface Squamous Neoplasia: Clinicopathological Analysis and Treatment Outcome of 65 Cases. J Coll Physicians Surg Pak. 2020; 30(9):970-973. DOI: 10.29271/jcpsp.2020.09.970. View

19.

Kaliki S, Kamal S, Fatima S . Ocular surface squamous neoplasia as the initial presenting sign of human immunodeficiency virus infection in 60 Asian Indian patients. Int Ophthalmol. 2016; 37(5):1221-1228. DOI: 10.1007/s10792-016-0387-0. View

20.

Meel R, Dhiman R, Vanathi M, Pushker N, Tandon R, Devi S . Clinicodemographic profile and treatment outcome in patients of ocular surface squamous neoplasia. Indian J Ophthalmol. 2017; 65(10):936-941. PMC: 5678328. DOI: 10.4103/ijo.IJO_251_17. View